US EditionPublished • loading... • Updated
Evaluating Eli Lilly (LLY) After Foundayo’s Slow Start And Recent Share Price Weakness
Summary by Simply Wall St
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Evaluating Eli Lilly (LLY) After Foundayo’s Slow Start And Recent Share Price Weakness
Fresh prescription data for Eli Lilly (LLY) put its new oral GLP-1 pill Foundayo under the microscope, with early use lagging Novo Nordisk’s Wegovy and Zepbound scripts also softening and pressuring the stock. See our latest analysis for Eli Lilly. The stock has pulled back in recent weeks, with a 1 day share price return of 3.67% decline and a 90 day share price return of 16.82% decline, even as headlines focus on Foundayo’s slower start, Kelon…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
